Pacira Pharmaceuticals, Inc. Sustainability Profile
Pacira Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on innovative solutions for pain management and surgical care. Founded in 2006, Pacira has made significant strides in the industry, particularly with its flagship product, EXPAREL, a long-acting local anaesthetic that enhances postoperative pain control while reducing the need for opioids. With a commitment to advancing patient care, Pacira operates primarily in North America and has expanded its reach into various surgical specialties. The company is recognised for its unique approach to pain management, positioning itself as a pioneer in the development of non-opioid therapies. Notable achievements include a strong market presence and partnerships that further its mission to improve surgical outcomes and patient recovery.
DitchCarbon Score
How does Pacira Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pacira Pharmaceuticals, Inc.'s score of 25 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pacira Pharmaceuticals, Inc.'s reported carbon emissions
Pacira Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures in kg CO2e. The company is a current subsidiary of Pacira BioSciences, Inc., which may influence its climate commitments and reporting practices. Despite the lack of direct emissions data, Pacira Pharmaceuticals has not publicly outlined any specific reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges noted in the available information. As a subsidiary, Pacira Pharmaceuticals may inherit climate-related strategies and data from its parent company, Pacira BioSciences, Inc., but specific details on emissions or reduction initiatives from this source are not provided. The absence of concrete data highlights a potential area for improvement in transparency and commitment to climate action within the pharmaceutical industry.
How Carbon Intensive is Pacira Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Pacira Pharmaceuticals, Inc.'s Location?
Pacira Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pacira Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.